Delcath Systems, Inc. (NASDAQ:DCTH) Shares Sold by AIGH Capital Management LLC

AIGH Capital Management LLC trimmed its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,385,389 shares of the company's stock after selling 397,101 shares during the quarter. Delcath Systems accounts for 5.2% of AIGH Capital Management LLC's portfolio, making the stock its 6th largest position. AIGH Capital Management LLC owned approximately 4.33% of Delcath Systems worth $16,680,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DCTH. Principal Financial Group Inc. bought a new position in Delcath Systems in the third quarter valued at approximately $808,000. Baader Bank Aktiengesellschaft bought a new stake in Delcath Systems in the 4th quarter valued at $204,000. Barclays PLC bought a new stake in Delcath Systems in the 3rd quarter valued at $104,000. Jane Street Group LLC acquired a new position in Delcath Systems in the 3rd quarter worth $110,000. Finally, Private Advisor Group LLC bought a new position in Delcath Systems during the 4th quarter worth about $153,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Trading Up 3.3 %

Shares of NASDAQ DCTH traded up $0.41 during mid-day trading on Wednesday, hitting $12.98. The company had a trading volume of 409,693 shares, compared to its average volume of 341,547. The firm has a 50-day simple moving average of $14.51 and a two-hundred day simple moving average of $12.09. The company has a market capitalization of $433.57 million, a PE ratio of -9.61 and a beta of 0.82. Delcath Systems, Inc. has a one year low of $4.26 and a one year high of $16.97.

Remove Ads

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.96 million. During the same quarter in the prior year, the business earned ($0.48) earnings per share. Sell-side analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. HC Wainwright boosted their price target on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, March 7th. Craig Hallum boosted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.